X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse IPCA Labs with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TEVA PHARMA (Israel) - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   TEVA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
TEVA PHARMA
Dec-13
IPCA LABS/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6953,069-   
Low Rs4002,666-   
Sales per share (Unadj.) Rs260.21,761.4-  
Earnings per share (Unadj.) Rs19.0110.0-  
Cash flow per share (Unadj.) Rs33.1252.4-  
Dividends per share (Unadj.) Rs1.0096.32-  
Dividend yield (eoy) %0.23.4 5.4%  
Book value per share (Unadj.) Rs213.01,956.6-  
Shares outstanding (eoy) m126.20848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.11.6 129.3%   
Avg P/E ratio x28.926.1 110.8%  
P/CF ratio (eoy) x16.611.4 145.8%  
Price / Book Value ratio x2.61.5 175.4%  
Dividend payout %5.387.5 6.0%   
Avg Mkt Cap Rs m69,1202,431,784 2.8%   
No. of employees `00013.344.9 29.5%   
Total wages/salary Rs m7,3590-   
Avg. sales/employee Rs Th2,477.433,233.7 7.5%   
Avg. wages/employee Rs Th555.20-   
Avg. net profit/employee Rs Th180.62,076.1 8.7%   
INCOME DATA
Net Sales Rs m32,8361,493,688 2.2%  
Other income Rs m4180-   
Total revenues Rs m33,2541,493,688 2.2%   
Gross profit Rs m4,505409,047 1.1%  
Depreciation Rs m1,777120,736 1.5%   
Interest Rs m24029,338 0.8%   
Profit before tax Rs m2,905258,973 1.1%   
Minority Interest Rs m01,176 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-170,001 0.0%   
Tax Rs m511-3,162 -16.2%   
Profit after tax Rs m2,39493,310 2.6%  
Gross profit margin %13.727.4 50.1%  
Effective tax rate %17.6-1.2 -1,440.9%   
Net profit margin %7.36.2 116.7%  
BALANCE SHEET DATA
Current assets Rs m19,4551,008,832 1.9%   
Current liabilities Rs m10,076879,786 1.1%   
Net working cap to sales %28.68.6 330.6%  
Current ratio x1.91.1 168.4%  
Inventory Days Days9891 107.8%  
Debtors Days Days6796 69.8%  
Net fixed assets Rs m20,260487,872 4.2%   
Share capital Rs m2523,677 6.9%   
"Free" reserves Rs m26,6330-   
Net worth Rs m26,8861,659,204 1.6%   
Long term debt Rs m2,340763,756 0.3%   
Total assets Rs m41,1733,413,557 1.2%  
Interest coverage x13.19.8 133.3%   
Debt to equity ratio x0.10.5 18.9%  
Sales to assets ratio x0.80.4 182.3%   
Return on assets %6.43.6 178.1%  
Return on equity %8.95.6 158.3%  
Return on capital %10.84.9 218.2%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Net fx Rs m10,7590-   
CASH FLOW
From Operations Rs m3,411238,017 1.4%  
From Investments Rs m-1,354-84,339 1.6%  
From Financial Activity Rs m-1,304-285,517 0.5%  
Net Cashflow Rs m753-131,839 -0.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.53 Rs / USD

Compare IPCA LABS With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare IPCA LABS With: FDC LTD.  BIOCON LTD  WYETH LTD  DISHMAN PHARMA  JUBILANT LIFE SCIENCES  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views On News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Oct 17, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS